TherapeuticsMD, Inc.
TherapeuticsMD, Inc. is a U.S.-based pharmaceutical royalty company focused on women’s healthcare products. Through licensing arrangements, it receives royalties tied to branded prescription products including IMVEXXY, BIJUVA, ANNOVERA, and prenatal vitamin brands sold in the United States and its territories.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueRoyalty streams tied to licensed prescription products for menopause, contraception, and prenatal care.
Royalties from prescription prenatal vitamin products sold under BocaGreenMD and vitaMedMD.
Customers
TherapeuticsMD’s direct commercial counterparties are pharmaceutical licensees and distributors that market its licensed products in the United States and its territories. End demand comes from women treated for menopause-related symptoms, contraception needs, and prenatal supplementation, but the company itself monetizes that demand through royalty agreements rather than direct sales. Its revenue therefore depends on the commercial execution of its licensees and the underlying prescription volumes of the branded products.
Mayne Pharma and other commercial partners pay royalties and market the licensed products.
Patients using IMVEXXY and BIJUVA for menopause-related symptoms drive royalty-bearing sales.
Users of ANNOVERA generate prescription volume for the licensed contraceptive product.
Patients and prescribers using BocaGreenMD and vitaMedMD prenatal vitamins support royalty income.
Strategy
TherapeuticsMD’s strategy is to monetize its women’s healthcare portfolio through royalty and license agreements rather than direct commercialization. The business depends on protecting its contractual rights, collecting royalties from licensees, and preserving the value of its branded product portfolio. Because revenue is driven by partner sales, the company’s strategic focus is on license enforcement, dispute resolution, and maintaining the economic terms of its agreements.
Royalty income is the company’s core operating model and main source of revenue.
Disputes over rebates, returns, and working capital can change cash receipts and reported revenue.
The royalty stream depends on continued market demand for the underlying products.
Geography
Q1/2026The company’s royalty portfolio is concentrated in the United States and its possessions and territories, where the licensed products are commercialized. That geographic concentration makes revenue dependent on U.S. prescription demand, payer access, and the execution of its U.S. licensee. The business has limited operating geography because it no longer runs a direct commercial or R&D platform.
Share of the revenue the company reports by geography.
Risks
TherapeuticsMD faces concentrated counterparty risk because most of its economics depend on a small number of license agreements, especially with Mayne Pharma. The company also carries litigation, royalty-calculation, and going-concern risk, since lower-than-expected partner sales or adverse dispute outcomes could reduce cash inflows and strain liquidity. As a royalty business, it is also exposed to prescription demand trends, payer access, and execution risk at the licensee level rather than its own commercial operations.
- Going-concern and liquidity pressureImpact: CriticalLikelihood: High
The company disclosed substantial doubt about its ability to continue as a going concern if cash inflows disappoint.
Exposure: Cash reserves and operating continuity
- Mayne Pharma contractual disputesImpact: HighLikelihood: High
Allowance calculations, returns, rebates, and working-capital true-ups can alter revenue and cash collections.
Exposure: Royalty receivables and license revenue
- Concentration in a few licensed productsImpact: High
A small portfolio means sales declines in one product can materially affect total royalties.
Exposure - Licensee execution riskImpact: MediumLikelihood: Low
TherapeuticsMD relies on third parties for commercialization, supply chain, and market access.
Exposure: Mayne Pharma commercialization and contract manufacturers
Accounting
Judgemental itemsRevenue is tied to licensee sales and contractual royalty formulas, so timing and estimates matter.
Impact: Affects reported license revenue and receivables
Management and Mayne Pharma dispute these calculations, which can change recognized revenue and cash due.
Impact: Affects net revenue and working-capital settlements
The company carries short- and long-term receivables from Mayne Pharma that depend on future payments.
Impact: Affects balance sheet valuation and liquidity assessment
Prior asset sales and discontinued operations can require impairment or write-off judgments.
Impact: Affects operating expenses and asset values
Similar listed companies
Publicly listed companies with a comparable business focus.
Turn Therapeutics Inc.
TTRX · Pharmaceutical Preparations
United Therapeutics Corporation
UTHR · Pharmaceutical Preparations
United Therapeutics is a U.S.-based biopharmaceutical company focused on therapies for pulmonary arterial hypertension and other serious rare diseases, along with organ manufacturing technologies.
Context Therapeutics Inc.
CNTX · Pharmaceutical Preparations
TG Therapeutics, Inc
TGTX · Pharmaceutical Preparations
TG Therapeutics is a U.S.-based biopharmaceutical company focused on developing and commercializing treatments for B-cell diseases and related immune-mediated disorders.
Transcode Therapeutics, Inc.
RNAZ · Pharmaceutical Preparations
Metagenomi Therapeutics, Inc.
MGX · Biological Products, (No Diagnostic Substances)
Last updated: 24/09/2026